Syndax Announces Participation at Two Upcoming Investor Conferences
- A fireside chat at the Guggenheim 6th Annual
Biotechnology Conferenceat 10:00 a.m. ETon Thursday, February 8, 2024in New York, NY.
- A fireside chat at the Citi 2024 Virtual Oncology Leadership Summit at 2:00 p.m. ET on
Wednesday, February 21, 2024.
A live webcast of the fireside chats can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.